|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Entresto
|
|
gptkbp:class
|
angiotensin receptor neprilysin inhibitor
|
|
gptkbp:clinical_trial
|
gptkb:PARADIGM-HF
chronic heart failure
acute heart failure
|
|
gptkbp:contains
|
gptkb:sacubitril
valsartan
|
|
gptkbp:contraindication
|
pregnancy
angioedema
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:education
|
recognizing side effects
importance of adherence
monitoring potassium levels
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:has_ability
|
49 mg/51 mg
97 mg/103 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Entresto
|
|
gptkbp:indication
|
heart failure with preserved ejection fraction
reduced ejection fraction heart failure
|
|
gptkbp:ingredients
|
gptkb:sacubitril
valsartan
|
|
gptkbp:interacts_with
|
lithium
diuretics
NSAI Ds
|
|
gptkbp:invention
|
2026
|
|
gptkbp:is_used_for
|
heart failure
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
pharmacokinetics
pharmacodynamics
mechanism of action
|
|
gptkbp:population
|
adults
pediatric patients
|
|
gptkbp:previous_name
|
gptkb:sacubitril/valsartan
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_information_on
|
ACC/ AHA guidelines
ESC guidelines
|
|
gptkbp:research
|
gptkb:DAPA-HF_study
gptkb:PARADIGM-HF_study
gptkb:PROVE-HF_study
H Fp EF study
|
|
gptkbp:safety_features
|
drug interactions
adverse reactions
black box warning
warnings and precautions
|
|
gptkbp:side_effect
|
cough
hypotension
hyperkalemia
|
|
gptkbp:traded_on
|
gptkb:Entresto
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
3
|